The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells-Reference-Cited by-同舟云学术

The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells

Published:2017-09-18 Issue:6 Volume:59 Page:1439-1450
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Iriyama Noriyoshi¹,Hino Hirotsugu²,Moriya Shota²,Hiramoto Masaki²,Hatta Yoshihiro¹,Takei Masami¹,Miyazawa Keisuke²

Affiliation:

1. Department of Medicine, Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan;

2. Department of Biochemistry, Tokyo Medical University, Tokyo, Japan

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1376741

Reference48 articles.

1. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

2. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

3. Novel agents in the treatment of multiple myeloma: a review about the future

4. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

5. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blocking ACSL6 Compromises Autophagy via FLI1‐Mediated Downregulation of COLs to Radiosensitize Lung Cancer;Advanced Science;2024-08-29

2. Modulation of autophagy and apoptosis can contribute to the anticancer effect of Abemaciclib/Celecoxib combination in colon cancer cells;Medical Oncology;2024-01-03

3. CDK4/6 and autophagy inhibitors synergize to suppress the growth of human head and neck squamous cell carcinomas;Molecular Carcinogenesis;2023-05-03

4. CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges;Cancers;2023-02-03

5. Controlling cell proliferation by targeting cyclin-dependent kinase 6 using drug repurposing approach;Control of Cell Cycle & Cell Proliferation;2023